News Headlines

  1. AmMax Bio Licenses Antibody-Drug Conjugate Technology For Hematological Cancers From Lonza 6/9/2026

    AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing an innovative portfolio of antibody-drug conjugates in oncology, and Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced a non-exclusive licensing agreement.

  2. SK bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development 6/9/2026

    SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that, after entering into a license agreement with the U.S. Centers for Disease Control and Prevention (CDC), it has initiated process development for an injectable rotavirus vaccine candidate.

  3. Matica Biotechnology Announces Engagement By University Health Network (UHN) To Supply cGMP Manufacturing Of IL-10 Adenoviral Therapy For Lung Transplantation 6/9/2026

    Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector contract development and manufacturing organization (CDMO) specializing in advanced therapies, is pleased to announce its engagement with University Health Network (UHN).

  4. Everest Medicines Enters Into Asset Purchase Agreement With Corxel Pharmaceuticals To Develop And Commercialize LNZ100 In Greater China 6/8/2026

    Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Limited ("CORXEL").

  5. Chime Biologics Deepens Collaboration With Cytiva To Boost Manufacturing Capacity 6/8/2026

    Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, today announced the inauguration of its GMP-2 manufacturing facility in Wuhan, China, further expanding its capacity to support growing global demand for biologics.

  6. Recipharm And Fusix Biotech Advance Novel Oncolytic Virus Platform 6/8/2026

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on innovative oncolytic virus technology.

  7. Made Scientific Selected As Manufacturer For Columbia University's Autologous And Allogeneic NOVAKnee Program - A First-In-Class Living Biologic Total Knee Replacement 6/5/2026

    Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), today announced it has been selected as manufacturer for NOVAKnee, a first-in-class living biologic total knee replacement being developed by researchers at Columbia University's School of Engineering and Vagelos College of Physicians and Surgeons under the Advanced Research Projects Agency for Health (ARPA-H) Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program.

  8. Stipple Bio Enters Multi-Target License Agreement With Lonza To Advance Precision Oncology ADC Therapies 6/4/2026

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced a multi-target licensing agreement to support the development of next-generation precision oncology ADC therapies.

  9. Made Scientific And Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership To Advance Next-Generation iPSC-Derived Cell Therapies 6/4/2026

    Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Pluristyx, a leading provider of RUO and GMP induced pluripotent stem cell (iPSC) platform technologies, today announced a strategic partnership to integrate Pluristyx Technology including GMP iPSC lines and derivative cell types, including induced natural killer (iNK) cells and induced mesenchymal stem cells (iMSCs), into Made Scientific's end-to-end CDMO offering for global cell and gene therapy innovators.

  10. Veranova Appoints Dr. Bob Huang Vice President And General Manager Of West Deptford Site 6/3/2026

    Veranova today announced the appointment of Dr. Bob Huang as Vice President and General Manager for its West Deptford, New Jersey facility. He will lead site operations, advance strategic growth initiatives, and strengthen manufacturing excellence and customer delivery.